Inovio Pharmaceuticals Inc ($INO) Stock Forecast: Up 23.2% Today

What is Inovio Pharmaceuticals Inc?

INO, or Inovio Pharmaceuticals, is a biotechnology company focused on developing DNA medicines to treat HPV-associated diseases, cancer, and infectious diseases. Today, the stock had a strong bullish movement.

Why is Inovio Pharmaceuticals Inc going up?

INO stock is up 23.2% on Jan 7, 2024 14:05

• Inovio stock surged to a seven-month high due to a clinical trial pact and plans to file a marketing application. This positive news likely generated investor optimism and drove the bullish movement.
• INOVIO announced a clinical collaboration and supply agreement with Coherus BioSciences to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for head and neck cancer. This collaboration may have boosted investor confidence and contributed to the bullish market movement.
• Additionally, Inovio's plans to submit a Biologics License Application (BLA) for INO-3107, a potential treatment for Recurrent Respiratory Papillomatosis, in the second half of 2024 may have further fueled investor enthusiasm and contributed to the bullish movement.

INO Price Chart

INO News

Inovio stock surges to seven-month high

Inovio Pharmaceuticals (INO) stock surges to reach a seven month high on the back of a clinical trial pact and a plans to file a marketing application. Read more here.

https://seekingalpha.com/news/4052738-inovio-stock-surges-seven-month-high?feed_item_type=news

INOVIO Enters Clinical Collaboration And Supply Agreement With Coherus BioSciences

WASHINGTON (dpa-AFX) - INOVIO (INO) announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. (CHRS) to evaluate the combination of INO-3112 and LOQTORZI as a potentia…

https://www.finanznachrichten.de/nachrichten-2024-01/61060021-inovio-enters-clinical-collaboration-and-supply-agreement-with-coherus-biosciences-020.htm

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

- Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced , high-risk , HPV16/18 - positive head and neck cancer PLYMOUTH MEETING, Pa. and REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. ((Coherus, NASDAQ: CHRS ) to evaluate the combination of INO-3112 and LOQTORZI™ (toripalimab-tpzi) as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer commonly known as throat cancer. Under the terms of the supply agreement, Coherus will provide LOQTORZI™ (toripalimab-tpzi), for a Phase 3 clinical trial to be conducted by INOVIO, pending alignment with the U.S.

https://www.benzinga.com/pressreleases/24/01/n36488058/inovio-and-coherus-announce-clinical-collaboration-to-advance-development-of-ino-3112-in-combinati

Inovio plans to submit BLA to FDA for INO-3107 in 2H

No summary available.

https://seekingalpha.com/news/4051925-inovio-plans-to-submit-bla-to-fda-for-ino-3107-in-2h?feed_item_type=news

INOVIO Plans To Submit BLA For INO-3107 In H2

WASHINGTON (dpa-AFX) - INOVIO (INO) announced plans to submit a BLA for INO-3107 as a potential treatment for Recurrent Respiratory Papillomatosis in the second half of 2024. This followed an Init…

https://www.finanznachrichten.de/nachrichten-2024-01/61050081-inovio-plans-to-submit-bla-for-ino-3107-in-h2-020.htm

Trending Today

Bittensor ($TAO) Crypto Forecast: Up 8.4% Today

Avalanche ($AVAX) Crypto Forecast: Up 5.1% Today

Sui ($SUI) Crypto Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Up 5.2% Today

Fantom ($FTM) Crypto Forecast: Down 5.1% Today

Bonk ($BONK) Crypto Forecast: Up 7.0% Today

Stox ($STX) Crypto Forecast: Up 10.3% Today

Aptos ($APT) Crypto Forecast: Up 12.4% Today

Ethereum ($ETH) Crypto Forecast: Up 5.8% Today

Fetch.ai ($FET) Crypto Forecast: Up 6.4% Today

Inovio Pharmaceuticals Inc Price History

28.10.2023 - INO Stock was down 1.6%

• The bearish movement in INO's stock could be attributed to the initiation of coverage by StockNews.com. This coverage might have provided a negative outlook or raised concerns about the company's prospects, leading to a decrease in investor confidence.
• It is possible that the coverage highlighted potential challenges or risks associated with Inovio Pharmaceuticals' products or pipeline, causing investors to sell off their positions.
• The bearish movement could also be influenced by broader market trends or sector-specific factors impacting the biotechnology industry as a whole.

07.00.2024 - INO Stock was up 23.2%

• Inovio stock surged to a seven-month high due to a clinical trial pact and plans to file a marketing application. This positive news likely generated investor optimism and drove the bullish movement.
• INOVIO announced a clinical collaboration and supply agreement with Coherus BioSciences to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for head and neck cancer. This collaboration may have boosted investor confidence and contributed to the bullish market movement.
• Additionally, Inovio's plans to submit a Biologics License Application (BLA) for INO-3107, a potential treatment for Recurrent Respiratory Papillomatosis, in the second half of 2024 may have further fueled investor enthusiasm and contributed to the bullish movement.